Compare
Up to four compounds, side by side.
Search or pick a starting set. Differences light up so you can spot them fast.
TesamorelinAOD-96045-Amino-1MQ
3 / 4
Overview
Summary
The visceral-fat peptide — FDA-approved for HIV-associated lipodystrophy.
GH-fragment with lipolytic action and no growth signaling.
NNMT inhibitor for fat loss and metabolic health.
Category
Growth Hormone Releasing Hormone Analog
Metabolic
Metabolic
Mechanism
A stabilized GHRH analog. Selectively reduces visceral adipose tissue in studied populations.
Modified C-terminal fragment of GH. Promotes lipolysis without affecting IGF-1.
NNMT inhibitor. Preserves NAD+ and SAM, supporting metabolism and adipocyte function.
Effects
Top outcomes
- Fat loss92
- Cognition60
- Lean muscle55
- Fat loss70
- Fat loss75
- Energy60
Evidence
Established
Emerging
Anecdotal
Practical
Half-life
~26 min (peptide), but downstream GH effect lasts hours
Short
Several hours (oral)
Administration
subq
subq
oral
Risk
Legal status
rx only
research only
research only
Safety
Generally well tolerated; injection-site reactions most common.
Well tolerated in trials; efficacy modest.
Limited human data.
Try a preset